A Robust Pipeline
 Powered by Brave Science

Areas of investigation include potential new treatments in neurology, neuroendocrinology, and neuropsychiatry. Our pipeline exemplifies scientific excellence that addresses unmet clinical needs.

Filter By

  • Phase 1
  • Phase 2
  • Phase 3
  • Neurology
  • Neuropsychiatry
  • Adjunctive Treatment
of Schizophrenia
  • CNS Indications
  • Dyskinetic Cerebral Palsy
  • Epilepsy
  • Inadequate Response to Treatment in Major Depressive Disorder
  • Major Depressive Disorder
  • Movement Disorders
  • Schizophrenia
|

  • PROGRAM (TARGET)

    valbenazine*
    (VMAT2 Inhibitor)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    Adjunctive Treatment
of Schizophrenia
    Phase 1
    Phase 2
    Phase 3
    phase3

  • PROGRAM (TARGET)

    valbenazine*
    (VMAT2 Inhibitor)

    THERAPEUTIC AREA

    Neurology

    INDICATION

    Dyskinetic Cerebral Palsy
    Phase 1
    Phase 2
    Phase 3
    phase3

  • PROGRAM (TARGET)

    osavampator/NBI-'845±
    (AMPA)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    Inadequate Response to Treatment in Major
Depressive Disorder
    Phase 1
    Phase 2
    Phase 3
    phase3

  • PROGRAM (TARGET)

    NBI-'568‖
    (M4 Agonist)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    Schizophrenia
    Phase 1
    Phase 2
    Phase 3
    phase3

    PROGRAM (TARGET)

    NBI-'570‖
    (M1/M4 Agonist)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    Schizophrenia
    Phase 1
    Phase 2
    Phase 3
    phase1

  • PROGRAM (TARGET)

    NBI-'770§
    (NMDA NR2B NAM)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    Major Depressive Disorder
    Phase 1
    Phase 2
    Phase 3
    phase2

  • PROGRAM (TARGET)

    NBI-'567‖,¶
     (M1 Agonist)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    CNS Indications
    Phase 1
    Phase 2
    Phase 3
    phase1

    PROGRAM (TARGET)

    NBI-'569‖
    (M4 Agonist)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    CNS Indications
    Phase 1
    Phase 2
    Phase 3
    phase1

    PROGRAM (TARGET)

    NBI-'890
    (VMAT2 inhibitor)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    CNS Indications
    Phase 1
    Phase 2
    Phase 3
    phase1

    PROGRAM (TARGET)

    NBI-'675
    (VMAT2 Inhibitor)

    THERAPEUTIC AREA

    Neuropsychiatry

    INDICATION

    CNS Indications
    Phase 1
    Phase 2
    Phase 3
    phase1

  • PROGRAM (TARGET)

    NBI-'986
    (M4 Antagonist)

    THERAPEUTIC AREA

    Neurology

    INDICATION

    Movement Disorders
    Phase 1
    Phase 2
    Phase 3
    phase1

  • PROGRAM (TARGET)

    NBI-'355
    (Nav1.2/1.6)

    THERAPEUTIC AREA

    Neurology

    INDICATION

    Epilepsy
    Phase 1
    Phase 2
    Phase 3
    phase1

Neurocrine Biosciences has global rights unless otherwise noted.

*Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.

±Takeda Pharmaceutical Company Limited has retained rights in Japan.

§Licensed from Takeda Pharmaceutical Company Limited.

‖Licensed from Nxera Pharma (formerly Sosei Heptares).

Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

Download Pipeline Chart

Investor Relations

Learn More

Clinical Studies

Check Out What We’re Studying

Career Opportunities

Work With Us

You are leaving
Neurocrine.com

Exit Site